<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846362</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2018-05</org_study_id>
    <nct_id>NCT03846362</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML</brief_title>
  <official_title>A Prospective Multicenter Clinical Trial of Treatment Strategy Based on MRD Level After 2 Initial Courses of Chemotherapy in Children and Young Adults With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Physicians, Innovations, Science for Children Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain
      reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control
      parameter for the optimal therapy tactics.

      Patients with initially high-risk group and those with high MRD after 2 initial courses of
      chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem
      cells from Human Leucocyte Antigen (HLA) matched or haploidentical family donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genetic alterations in acute myeloid leukemia (AML) clone are well known prognostic risk
      factors of AML relapse. Standard risk group includes favorable t (15;17) (q22; q21) and inv
      (16)/t (16;16). High-risk patients have a complex karyotype rearrangement (3 and more),
      inversion of the long arm in 3rd chromosome and EVI1 gene rearrangement, monosomy 5 and 7,
      translocations involving KMT2A gene and several rare translocations. All other genotype
      alterations attributed to the moderate risk group.

      Besides genetic factors, detection of the minimal residual disease (MRD) after initial
      chemotherapy and its decrease rate after 1st postremission chemotherapy with high dose
      Cytarabine and anthracyclines, plays a crucial role in the development of the morphologic
      relapse. Patients with PCR-MRD&lt;0,1% after 2 courses of chemotherapy have a 30% or less risk
      of relapse, while PCR-MRD&gt;0,1% - over 70%. In the clinical trial investigators are planning
      to measure MRD either by immune-phenotype, or PCR methods, in 3 check-points and it will be
      one of decision-making control parameter for the optimal therapy tactics.

      Patients with initially high-risk group and those with high MRD after 2 initial courses of
      chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem
      cells from HLA- matched or haploidentical family donors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse-free survival (RFS)</measure>
    <time_frame>1 year</time_frame>
    <description>relapse-free survival from date of diagnosis till date of relapse, or date of death (whichever comes first) or date of last follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Event=relapse/nonresponse, death or second malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of of patients with severe adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of of patients with severe adverse effects of therapy according to CTCAE (ver 4.3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of of patients with severe infections</measure>
    <time_frame>1 month</time_frame>
    <description>The proportion of of patients with severe infections: number of episodes, grade, after each course of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of of patients with severe cardiotoxicity</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of of patients with severe cardiotoxicity: number of episodes and %EF by echocardiogam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD dynamic</measure>
    <time_frame>1 months</time_frame>
    <description>MRD (IFT and/or PCR) dynamic between check-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD specificity and sensitivity</measure>
    <time_frame>1, 2, 3 months</time_frame>
    <description>MRD specificity and sensitivity in relapse prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>6 months, 1 year</time_frame>
    <description>competing event - death in CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant-related mortality</measure>
    <time_frame>6 months after HSCT</time_frame>
    <description>for transplanted patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of aGvHD II-IV grade</measure>
    <time_frame>100 days after HSCT</time_frame>
    <description>for transplanted patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of cGvHD</measure>
    <time_frame>1 year after HSCT</time_frame>
    <description>for transplanted patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia, Childhood</condition>
  <arm_group>
    <arm_group_label>intermediate risk MRD2&gt;0,1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRD2&gt;0,1% - FLA - MRD3 - HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HSCT</intervention_name>
    <description>allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2&gt;0,1% and initial intermediate risk</description>
    <arm_group_label>intermediate risk MRD2&gt;0,1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. de novo acute myeloid leukemia

          2. signed informed consent

        Exclusion Criteria:

        diagnosis of: Fanconi anemia, acute promyelocytic leukemia, MDS, JMML, AML as secondary
        malignancy, Dawn syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey Maschan</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Pediatric Hematology , Moscow, Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Maschan</last_name>
    <role>Study Director</role>
    <affiliation>National Research Center for Pediatric Hematology , Moscow, Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Galina Novichkova</last_name>
    <role>Study Chair</role>
    <affiliation>National Research Center for Pediatric Hematology , Moscow, Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irina Kalinina</last_name>
    <phone>+7 495 287 65 70</phone>
    <phone_ext>7425</phone_ext>
    <email>oml-registration@fnkc.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhanna Shekhovtsova</last_name>
    <phone>+7 495 287 65 70</phone>
    <phone_ext>7538</phone_ext>
    <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital â„– 1</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk Oblast</state>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleg Arakaev</last_name>
      <phone>(343) 231-91-09</phone>
    </contact>
    <investigator>
      <last_name>Larisa Fechina, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Kalinina</last_name>
      <phone>84956647078</phone>
      <phone_ext>7432</phone_ext>
      <email>oml-registration@fnkc.ru</email>
    </contact>
    <contact_backup>
      <last_name>Zhanna Shekhovtsova</last_name>
      <phone>84956647078</phone>
      <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Maschan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MRD</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>pediatric</keyword>
  <keyword>leukemia</keyword>
  <keyword>haploidentical</keyword>
  <keyword>TcRab-depletion</keyword>
  <keyword>young adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

